Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Sponsored by Maimónides Biomedical Research Institute of Córdoba
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 3 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Age ≥ 18 and < 90 years
- PCR confirmed diagnosis of COVID-19. As an alternative to PCR, a determination of antigens or any other test that in the future is considered equivalent to these in its diagnostic value may be accepted as evidence
- Radiological image compatible with inflammatory pleuropulmonary exudate or patients with onset of symptoms in the last 7 days and with an uncomplicated respiratory infection for outpatient follow-up.
- Signature of direct or delegated informed consent
Exclusion Criteria
- Being treated with Calcifediol or Cholecalciferol in any of its presentations and dosages
- Intolerance or allergy to Calcifediol or its components
- Pregnancy